Home > About Enantia > Patents


Your Investment Protected

Helping you gain intellectual property by generating novel and innovative chemical entities and processes

Request information

Patents can be viewed as one way to measure the sucess of a company.

Enantia is proud to have developed the chemistry for many processes since 2003.

As a result of our internal R&D programs and successful contribution to our clients projects, Enantia appears in more than 50 patent applications either as applicant or as inventor.

Apart from acting as a CRO, Enantia has become an active R&D player in the API arena through its internal projects. Thus Enantia has developed new chemical processes and API solid forms that have been patent protected, and later commercialised through a range of agreements with our partners. The IP generated at Enantia represents interesting commercial opportunities in the fields of API manufacturing and lifecycle management.

A selected list of products for which Enantia has contributed to a patent filing can be found below.

Patent applications filed as a result of service projects:

  • Quetiapine
  • Sartans
  • Delmopinol
  • Montelukast
  • Esomeprazole.
  • Omeprezole resolution by co-crystallization process
  • Sildenafil
  • Salts of COX-inhibitors
  • O-Demethylated-Tramadol co-crystals
  • Linezolid
  • Co-crystals of Tramadol
  • Co-crystal of Celecoxib
  • Metyrosine
  • Erlotinib
  • Pregablin
  • Dabigatran
  • Agomelatine
  • Telmisartan
  • Ivabradine
  • Ambrisentan
  • Lapatinib
  • Vilazadone

Patent applications filed as a result of internal R&D projects:

  • Gamma-Amino-vinyl sulphones (WO/2004/101504)
  • Valsartan (WO/2006/067216 and WO/2007/071750)
  • Adapalene (WO/2007/063522 and WO/2007/063523)
  • New ligands for Pauson-Khand reaction (WO/2008/046950)
  • Trans-(2R,4R)-4-Methylpipecolic acid (WO/2011/039290)
  • Rivaroxaban (WO/2011/080341A1)
  • Saxagliptin (WO/2013/60354A1)